Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTCY and uhCG/EGF for GVHD Prophylaxis in MMUD Stem Cell Transplant
NCT04886726Phase 1Recruiting
- Sponsor
- Henry Ford Health
- Start
- Dec 2021
- Primary completion
- Nov 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of urinary-derived human chorionic gonadotropin + epidermal growth factor in graft-versus-host disease (GVHD), sponsored by Henry Ford Health. Primary endpoints: Maximum Tolerated Dose at day 30 and Dose Limiting Toxicity at day 30. Started Dec 2021; status: recruiting.
02
Drugs
urinary-derived human chorionic gonadotropin + epidermal growth factor
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04886726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04886726.